Albany's AngioDynamics ($ANGO) announced that all FDA warning letters related to manufacturing at its facilities have been lifted. They dated from as far back as January 2011. "The removal of the final warning letters is a reflection of the exceptional quality and operations teams we have today at AngioDynamics. Over the past four years, they have worked diligently with the FDA to fully address the issues and help to instill a culture within the company that is committed to quality and compliance," said AngioDynamics CEO Joseph DeVivo in a statement. "The resolution of these issues is a significant boost to AngioDynamics and improves our ability to drive the growth of the business, especially in international markets." Release